T116. PREDICTION OF REMISSION IN NON-CONVERTING INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS
Authors: Worthington Michelle , Addington Jean , Bearden Carrie , Cadenhead Kristin , Cornblatt Barbara , Mathalon Daniel , McGlashan Thomas , Perkins Diana , Seidman Larry , Tsuang Ming , Walker Elaine , Woods Scott , Cannon Tyrone 
Published: May 2020

Abstract

Background
The clinical high-risk period before a first episode of psychosis (CHR-P) has been widely studied in the past 30 years with the goal of understanding the development of psychosis. Despite the progress in understanding what factors are associated with conversion to psychosis from the CHR-P state, less attention has been paid to the individuals who do not transition to psychosis. It is estimated that approximately 75–80% of individuals do not go on to convert to psychosis from the CHR-P state and this group should not simply be characterized as the inverse of conversion. To date, only a handful of studies have examined the characteristics and predictors of those who do not convert to psychosis and ultimately either remit or continue to meet symptom-based CHR-P criteria. The present study took an exploratory empirical approach to determining potential factors that predict remission in non-converters.

Methods
Participants were drawn from the North American Prodrome Longitudinal Study (NAPLS2). Univariate Kaplan Meier survival analyses were performed on a pool of available demographic and clinical variables. Variables that were significant (p &lt; 0.05) in the univariate analyses were then included in a multivariate Cox proportional hazard regression to predict remission. Remission was defined as all SOPS positive symptom subscale items rated as a 2 or lower at any given follow-up visit.

Results
A total of 359 participants from the NAPLS2 study who did not convert to psychosis and had data for at least the baseline and first follow-up visit and were included in this study. Of these participants, 174 met criteria for symptomatic remission. A total of 57 clinical variables were tested in univariate analyses and 14 of these variables met criteria for inclusion in the multivariate model. The variables included in the multivariate model were demographic variables (ethnicity, stressful life events), items from the Scale of Prodromal Symptoms (SOPS) (avolition, dysphoric mood), subtest scores from the MATRICS Cognitive Battery (speed of processing, verbal learning, verbal and non-verbal working memory, reasoning and problem solving, visual learning), one item from the Calgary Depression Scale for Schizophrenia (CDSS) (pathological guilt) and measures of functioning (GAF decline in past year, lowest GAF score in the past year). Overall, the multivariate model achieved a C-index of 0.64 (SE = 0.02) and p-value of 0.001 in predicting remission. In the multivariate model, significant covariates included stressful life events (HR = .95, p = .006), Hispanic ethnicity (HR = 1.45, p = .045), and avolition (HR = .89, p = .04). Covariates approaching significance included visual learning (HR = 1.02, p = .07), and GAF decline in the past year (HR = 1.01, p = .09).

Discussion
This study is the first to use a data-driven approach to systematically assess clinical and demographic predictors of symptomatic remission in individuals who do not convert to psychosis. The identified set of significant clinical variables is novel, suggesting that remission represents a unique clinical phenomenon and suggesting that further study is warranted to best understand factors contributing to resilience and recovery from the CHR-P period.